Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enliven Therapeutics (ELVN) Total Non-Current Liabilities (2022 - 2025)

Enliven Therapeutics has reported Total Non-Current Liabilities over the past 4 years, most recently at $14.6 million for Q3 2025.

  • Quarterly results put Total Non-Current Liabilities at $14.6 million for Q3 2025, down 13.96% from a year ago — trailing twelve months through Sep 2025 was $14.6 million (down 13.96% YoY), and the annual figure for FY2024 was $15.9 million, down 38.54%.
  • Total Non-Current Liabilities reached $14.6 million in Q3 2025 per ELVN's latest filing, down from $15.2 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $25.9 million in Q4 2023 and bottomed at $9.1 million in Q2 2023.
  • Median Total Non-Current Liabilities over the past 4 years was $14.9 million (2025), compared with a mean of $16.0 million.
  • The largest annual shift saw Total Non-Current Liabilities surged 166.54% in 2023 before it plummeted 44.18% in 2025.
  • Over 4 years, Total Non-Current Liabilities stood at $9.7 million in 2022, then soared by 166.54% to $25.9 million in 2023, then plummeted by 38.54% to $15.9 million in 2024, then dropped by 7.95% to $14.6 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for ELVN at $14.6 million in Q3 2025, $15.2 million in Q2 2025, and $14.0 million in Q1 2025.